SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; ...
The National Interest on MSN
Trump announces new class of battleships—named for himself
The hypothetical Trump-class battleship would displace between 30,000 and 40,000 tons—making them roughly two-thirds the size ...
Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage ...
Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...
Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...
Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback